American Well (AMWL) Q2 2026 Earnings Call Transcript
American Well (AMWL) reported Q2 2026 revenue of $52 million, down 26.6% year over year, with subscription revenue of $25.7 million and AMG revenue of $24.4 million. Adjusted EBITDA loss was $1.15 million and net loss was $9.6 million. Full-year guidance was narrowed to $200-$205 million revenue and improved adjusted EBITDA loss to $9-$7 million. The Defense Health Agency issued an intent to award a sole-source contract.
How this was made
The 30-second read
Why it matters
Traders can update expectations for 2026 revenue and profitability trajectory based on raised guidance, while monitoring whether the sole-source intent converts into a binding contract and how churn affects subscription growth.
Market read
Raised 2026 revenue and adjusted EBITDA loss outlook, plus a DHA sole-source intent, are the main near-term drivers; Q3 loss guidance and churn temper the upside.
What to watch
Q2 revenue decline is attributed to churn, and Q3 adjusted EBITDA guidance still implies losses due to internal project completion costs, which could cap upside despite raised full-year targets.
Background
American Well’s call discusses Q2 2026 performance, transformation toward an AI-powered care infrastructure platform, and a government procurement intent tied to its platform.
Ticker impact
American Well reported Q2 results and raised full-year revenue to $200M-$205M, plus raised adjusted EBITDA loss guidance to $9M-$7M.
Bias modestly positive for AMWL, with volatility around contract confirmation and the next-quarter loss profile.
The article contains fresh, decision-relevant guidance numbers and a new government procurement intent, but it also flags temporary higher costs in Q3 and ongoing subscription churn.
Market effects
Reinforces demand for telehealth infrastructure and AI-enabled care platforms in government healthcare procurement, potentially supporting the broader digital health narrative.
Primarily US government healthcare contracting signal; limited direct regional spillover beyond US healthcare IT.
Low global relevance; the catalyst is US Defense Health Agency procurement and US financial guidance.
Counterpoint
The DHA notice is only an intent to award, so the market may over-discount execution risk and timing uncertainty until a final contract is signed.
Key entities
- companyAmerican Well
AMWL, reported Q2 2026 results and issued raised full-year guidance plus a Defense Health Agency sole-source intent update.
- government_agencyDefense Health Agency
DHA issued an intent to award a sole-source contract directly to American Well for a platform transition.
- companyOracle Health
Named as one of the proprietary providers included in the DHA transition described in the article.
- companyPhilips
Named as one of the proprietary providers included in the DHA transition described in the article.
